The purpose of this study is to find the best treatment for Tourette's Syndrome (TS)-spectrum
obsessive-compulsive disorder (OCD), which includes symptoms of TS, e.g., repeated and
involuntary body movements (tics).
There are 2 parts to this study: In Part 1, patients are placed into 1 of 2 groups based on
type of OCD, determined by medical history and family member interviews. In Part 2, patients
are treated with fluvoxamine (FVX) for 8 weeks. If patients do not respond to FVX alone,
either haloperidol or an inactive placebo will be added to the FVX regimen; patients will
take this drug combination for 4 weeks. Patients will be monitored throughout the trial.
The purpose of this study is to find the best treatment for Tourette's Syndrome (TS)-spectrum
obsessive-compulsive disorder (OCD), which includes symptoms of TS, e.g., repeated and
involuntary body movements (tics).
There are 2 parts to this study: In Part 1, patients are placed into 1 of 2 groups based on
type of OCD, determined by medical history and family member interviews. In Part 2, patients
are treated with fluvoxamine (FVX) for 8 weeks. If patients do not respond to FVX alone,
either haloperidol or an inactive placebo will be added to the FVX regimen; patients will
take this drug combination for 4 weeks. Patients will be monitored throughout the trial.
The Study of Olanzapine Plus Fluoxetine in Combination for Treatment of Treatment Resistant Depression
Completed
Eli Lilly and Company
Phase 3
2002-04-01
The purposes of this study are to determine:
- Whether olanzapine plus fluoxetine in combination will help patients with
treatment-resistant major depression.
- The safety of olanzapine plus fluoxetine in combination, plus and any side effects that
might be associated with the combination.
- The effectiveness of olanzapine plus fluoxetine compared to olanzapine and fluoxetine
alone.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
